search
Back to results

Effectiveness of the HeartHab Application on Exercise Capacity in Patients With Coronary Artery Disease

Primary Purpose

Coronary Artery Disease

Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Use of HeartHab application followed by usual care
Usual care followed by the use of HeartHab application
Sponsored by
Hasselt University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Coronary Artery Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • History of coronary artery disease with or without intervention (PCI/CABG/conservative)
  • History of a cardiac rehabilitation (CR) program
  • Clinically stable without inducible ischemia or high risk ventricular arrhythmia, confirmed by the last available maximal ergospirometry test
  • Age ≥18 years
  • Willing and physically able to follow an app based telerehabilitation program and other study procedures in a four months follow-up period
  • Evidence of a personally signed and dated informed consent, indicating that the subject (or legally-recognised representative) has been informed of all pertinent aspects of the study
  • Possession of and/or able to use an Android smartphone
  • Dutch speaking and understanding

Exclusion Criteria:

  • Recent PCI or CABG procedure, and still included in a CR program
  • Orthopedic, neurologic or any other pathologic condition which makes the patient physically unable to follow an app based telerehabilitation program
  • Planned interventional procedure or surgery in the next four months
  • Pregnant females
  • Present cardiovascular complaints
  • Participation in other cardiac rehabilitation program trials, focusing on exercise outcome
  • Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study or a life expectancy of less than 4 months based on investigators judgement

Sites / Locations

  • Jessa Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

AB sequence

BA sequence

Arm Description

Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.

Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)

Outcomes

Primary Outcome Measures

Change in VO2peak
Exercise capacity is defined as the peak oxygen uptake, measured by CPET (cardiopulmonary exercise test)
Change in VO2peak
Exercise capacity is defined as the peak oxygen uptake, measured by CPET (cardiopulmonary exercise test)
Change in VO2peak
Exercise capacity is defined as the peak oxygen uptake, measured by CPET (cardiopulmonary exercise test)

Secondary Outcome Measures

Risk factor profile: physiological parameter
Blood pressure
Risk factor profile: physiological parameter
Diabetes
Risk factor profile: physiological parameter
Overweight
Risk factor profile: physiological parameter
Smoking
Risk factor profile: physiological parameter
Physical activity
Risk factor profile: physiological parameter
Blood pressure
Risk factor profile: physiological parameter
Diabetes
Risk factor profile: physiological parameter
Overweight
Risk factor profile: physiological parameter
Smoking
Risk factor profile: physiological parameter
Physical activity
Risk factor profile: physiological parameter
Blood pressure
Risk factor profile: physiological parameter
Diabetes
Risk factor profile: physiological parameter
Overweight
Risk factor profile: physiological parameter
Smoking
Risk factor profile: physiological parameter
Physical activity
Generic health status: questionnaire
EQ5D
Exercise capacity: questionnaire
IPAQ
Quality of life: questionnaire
Heart QoL
Generic health status: questionnaire
EQ5D
Exercise capacity: questionnaire
IPAQ
Quality of life: questionnaire
Heart QoL
Generic health status: questionnaire
EQ5D
Exercise capacity: questionnaire
IPAQ
Quality of life: questionnaire
Heart QoL
Cardiovascular events: clinical assessment
Collection of adverse events during follow up visit
Cardiovascular events: clinical assessment
Collection of adverse events during follow up visit
Cardiovascular events: clinical assessment
Collection of adverse events during follow up visit

Full Information

First Posted
March 26, 2017
Last Updated
February 26, 2018
Sponsor
Hasselt University
Collaborators
Jessa Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03102671
Brief Title
Effectiveness of the HeartHab Application on Exercise Capacity in Patients With Coronary Artery Disease
Official Title
HeartHab: a Prospective Cross-over Trial Investigating the Effectiveness of an App Based Telerehabilitation Program on Exercise Capacity, Lifestyle and Risk Factors in Patients With Coronary Artery Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
March 1, 2017 (Actual)
Primary Completion Date
January 1, 2018 (Actual)
Study Completion Date
January 1, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hasselt University
Collaborators
Jessa Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The recurrence of major cardiac events after infarction is very high, in some populations up to 20% in the first year. Optimal secondary prevention as organized in cardiac rehabilitation centers is effective in reducing both morbidity and mortality. However, many studies have shown that the participation and adherence rate in CR-programs is low in most European countries. Therefore, novel ways of delivering secondary prevention using information technology and self-monitoring are being explored. Hence, this study will investigate the effectiveness of a mobile, patient tailored, app based multidisciplinary telerehabilitation program (HeartHab app) in improving exercise capacity, lifestyle and risk factors in patients with coronary artery disease in a post-rehabilitation setting.
Detailed Description
Study design and population This study is a prospective double-arm, non-pragmatic, cross-over, randomized controlled trial. Approximately 30 subjects will be selected retrospectively from the cardiology database of the Jessa Hospital Hasselt. Subjects who do not violate any of the predefined exclusion criteria and have provided informed consent will be randomly assigned in a 1:1 ratio to the treatment strategies (AB sequence or BA sequence). After two months, each individual will be switched to the other treatment strategy. Measurements At baseline, after two months (+14 days) and after four months (+14 days), a clinical assessment, medical history, current medication therapy, fasting blood sample, maximal cardiopulmonary exercise test, pulmonary function and three completed questionnaires (HeartQol, IPAQ and EQ-5D) will be collected of all patients. A fourth questionnaire will be completed by all the patients, focusing on the usability of the HeartHab-application. Statistical analysis Data analysis will be performed using SPSS version 22 (SPSS Inc, Chicago, IL, USA) according to the intention-to-treat principle by assigned treatment group. Nonparametric alternatives will be used for parametric statistics in case assumptions for the latter are violated. The Shapiro-Wilk test will be used to assess normality. Paired t tests (parametric) or Wilcoxon signed rank tests (nonparametric) will be used for within-group analysis; independent t tests (parametric) or Mann-Whitney U tests (nonparametric) for between-group analysis. Chi-square tests will be used in case of categorical variables; Fisher's exact tests will be used when expected frequencies are small. The significance level for tests is 2-sided α=.05. The cost-effectiveness evaluation will be conducted from a society and patient perspective, taking into account both intervention and health care resource costs. As the majority of patients will be retired, productivity losses due to illness-related absence from the workplace will not be taken into account. Health care costs will be the aggregated costs of hospital admissions for cardiovascular reasons and also specialist visits and associated diagnostics. The cardiovascular rehospitalizations' related costs will be derived from invoices retrieved from the recruiting hospitals' financial departments. INAMI/RIZIV's nomenclature-based tariffs will define specialist visits and diagnostics denominations. Quality adjusted life years (QALYs) will be used as a generic measure of effectiveness. Estimates of QALYs will be derived from the EQ-5D questionnaire. The EQ-5D scores will be converted to utility scores. The utility estimates will be converted to adjusted mean QALYs by calculating the area under the curve (AUC) utility estimates for all time intervals for each patient, weighted by the length of follow-up at that time interval. The change from baseline utility (adjusted differential incremental QALYs) will then be calculated, using the multiple regression model to control for baseline utility differences. The incremental cost-effectiveness ratio (ICER) will be calculated (ICER¼(Cost intervention group - Cost control group)/(Effectiveness intervention group - Effectiveness control group)) to compare costs and outcomes (effectiveness) across both treatment groups. The incremental cost will be determined by the difference in total average cost per patient between the intervention group and control group. The incremental effectiveness will be estimated by the adjusted differential incremental QALYs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AB sequence
Arm Type
Experimental
Arm Description
Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
Arm Title
BA sequence
Arm Type
Experimental
Arm Description
Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
Intervention Type
Other
Intervention Name(s)
Use of HeartHab application followed by usual care
Intervention Description
use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
Intervention Type
Other
Intervention Name(s)
Usual care followed by the use of HeartHab application
Intervention Description
Usual care (2 months) followed by the use of HeartHab application (two months)
Primary Outcome Measure Information:
Title
Change in VO2peak
Description
Exercise capacity is defined as the peak oxygen uptake, measured by CPET (cardiopulmonary exercise test)
Time Frame
day1
Title
Change in VO2peak
Description
Exercise capacity is defined as the peak oxygen uptake, measured by CPET (cardiopulmonary exercise test)
Time Frame
month 2 + 14 days
Title
Change in VO2peak
Description
Exercise capacity is defined as the peak oxygen uptake, measured by CPET (cardiopulmonary exercise test)
Time Frame
month 4 + 14 days
Secondary Outcome Measure Information:
Title
Risk factor profile: physiological parameter
Description
Blood pressure
Time Frame
day 1
Title
Risk factor profile: physiological parameter
Description
Diabetes
Time Frame
day 1
Title
Risk factor profile: physiological parameter
Description
Overweight
Time Frame
day 1
Title
Risk factor profile: physiological parameter
Description
Smoking
Time Frame
day 1
Title
Risk factor profile: physiological parameter
Description
Physical activity
Time Frame
day 1
Title
Risk factor profile: physiological parameter
Description
Blood pressure
Time Frame
month 2 + 14 days
Title
Risk factor profile: physiological parameter
Description
Diabetes
Time Frame
month 2 + 14 days
Title
Risk factor profile: physiological parameter
Description
Overweight
Time Frame
month 2 + 14 days
Title
Risk factor profile: physiological parameter
Description
Smoking
Time Frame
month 2 + 14 days
Title
Risk factor profile: physiological parameter
Description
Physical activity
Time Frame
month 2 + 14 days
Title
Risk factor profile: physiological parameter
Description
Blood pressure
Time Frame
month 4 + 14 days
Title
Risk factor profile: physiological parameter
Description
Diabetes
Time Frame
month 4 + 14 days
Title
Risk factor profile: physiological parameter
Description
Overweight
Time Frame
month 4 + 14 days
Title
Risk factor profile: physiological parameter
Description
Smoking
Time Frame
month 4 + 14 days
Title
Risk factor profile: physiological parameter
Description
Physical activity
Time Frame
month 4 + 14 days
Title
Generic health status: questionnaire
Description
EQ5D
Time Frame
day 1
Title
Exercise capacity: questionnaire
Description
IPAQ
Time Frame
day 1
Title
Quality of life: questionnaire
Description
Heart QoL
Time Frame
day 1
Title
Generic health status: questionnaire
Description
EQ5D
Time Frame
month 2 + 14 days
Title
Exercise capacity: questionnaire
Description
IPAQ
Time Frame
month 2 + 14 days
Title
Quality of life: questionnaire
Description
Heart QoL
Time Frame
month 2 + 14 days
Title
Generic health status: questionnaire
Description
EQ5D
Time Frame
month 4 + 14 days
Title
Exercise capacity: questionnaire
Description
IPAQ
Time Frame
month 4 + 14 days
Title
Quality of life: questionnaire
Description
Heart QoL
Time Frame
month 4 + 14 days
Title
Cardiovascular events: clinical assessment
Description
Collection of adverse events during follow up visit
Time Frame
day 1
Title
Cardiovascular events: clinical assessment
Description
Collection of adverse events during follow up visit
Time Frame
month 2 + 14 days
Title
Cardiovascular events: clinical assessment
Description
Collection of adverse events during follow up visit
Time Frame
month 4 + 14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: History of coronary artery disease with or without intervention (PCI/CABG/conservative) History of a cardiac rehabilitation (CR) program Clinically stable without inducible ischemia or high risk ventricular arrhythmia, confirmed by the last available maximal ergospirometry test Age ≥18 years Willing and physically able to follow an app based telerehabilitation program and other study procedures in a four months follow-up period Evidence of a personally signed and dated informed consent, indicating that the subject (or legally-recognised representative) has been informed of all pertinent aspects of the study Possession of and/or able to use an Android smartphone Dutch speaking and understanding Exclusion Criteria: Recent PCI or CABG procedure, and still included in a CR program Orthopedic, neurologic or any other pathologic condition which makes the patient physically unable to follow an app based telerehabilitation program Planned interventional procedure or surgery in the next four months Pregnant females Present cardiovascular complaints Participation in other cardiac rehabilitation program trials, focusing on exercise outcome Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study or a life expectancy of less than 4 months based on investigators judgement
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul Dendale, prof. dr.
Organizational Affiliation
Hasselt University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jessa Hospital
City
Hasselt
ZIP/Postal Code
3500
Country
Belgium

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
30946021
Citation
Sankaran S, Dendale P, Coninx K. Evaluating the Impact of the HeartHab App on Motivation, Physical Activity, Quality of Life, and Risk Factors of Coronary Artery Disease Patients: Multidisciplinary Crossover Study. JMIR Mhealth Uhealth. 2019 Apr 4;7(4):e10874. doi: 10.2196/10874.
Results Reference
derived

Learn more about this trial

Effectiveness of the HeartHab Application on Exercise Capacity in Patients With Coronary Artery Disease

We'll reach out to this number within 24 hrs